Introduction
Activation of mitochondria and release of pro-apoptotic factors from the mitochondria into the cytosol are key events in the initiation of the final phases of apoptosis prior to the demise of the affected cell. Release of cytochrome c and (d)ATP from mitochondria into the cytosol results in the recruitment and activation of procaspase-9 to the APAF-1/cytochrome c apoptosome. Activated caspase-9 mediates cleavage of downstream effector caspases that execute degradation of substrate proteins to disrupt key regulatory pathways, activate other protease systems and endonucleases, which ultimately results in complete disintegration of the cell from within. Apart from cytochrome c, additional cell death-promoting factors are released from mitochondria. These include Smac, the second mitochondrial activator of caspases, and factors that initiate caspaseindependent execution of apoptosis including AIF and the serine protease Omi/HtrA2 (Martinou and Green, 2001; van Loo et al., 2002) .
Smac acts as a sensitizer for caspase activation by binding to inhibitor of apoptosis proteins (IAP) via a short N-terminal sequence that disrupts binding of caspases to the IAP BIR3 domain . Similar IAP-antagonizing properties were attributed recently to Omi/HtrA2 in addition to its serine protease activity (Suzuki et al., 2001; Verhagen et al., 2002) . Smac activity has been implied to fully depend on its propensity to alleviate caspase inhibition by IAPs. Especially caspase-3 and -9 are subject to inhibition by IAP proteins. In fact, Smac not only disrupts binding of IAPs to caspases, but was also shown to mediate activation of caspase-3 . Thus, inhibition of IAP proteins to promote caspase activation seems to be a central task of such pro-apoptotic factors released upon mitochondrial activation.
Facilitating caspase activation is not only relevant for the cytochrome c-initiated mitochondrial pathway but also for the death receptor pathway that relies on crosstalk to the mitochondria in the majority of cell types. More recently, Smac peptides derived from the Nterminus were shown to sensitize lymphoma cells for epothilone B and TRAIL induced apoptosis (Guo et al., 2002) . In addition, the local injection of high concentrations of N-terminally derived Smac peptides plus TRAIL induced regression of experimental glioblastoma in a murine xenotransplant model (Fulda et al., 2002) .
We previously observed that loss of caspase-3 due to mutation or transcriptional downregulation in breast cancer cells results in acquired drug resistance and the failure to undergo drug-induced apoptosis (Friedrich et al., 2001) . In addition, activation of mitochondria during drug-induced apoptosis was shown to depend on a caspase-mediated amplification loop (von Haefen et al., 2003) . In malignant tumors, the mitochondrial apoptosis signaling cascade is, however, more often disrupted due to loss of Bax or overexpression of Bcl-2 or Bcl-x L (Raisova et al., 2001; Sturm et al., 2001; Bosanquet et al., 2002; Hemmati et al., 2002; Mrozek et al., 2003; Radetzki et al., 2002; Schelwies et al., 2002; von Haefen et al., 2002) . Thus, mitochondrial apoptosis signaling and the caspase cascade are not only closely interconnected through positive feedback signaling, but are also often disturbed in cancer cells displaying either innate or secondary, acquired resistance to anticancer therapy.
Given the central role of Smac in amplifying the caspase cascade, we aimed to study Smac as a putative target for anticancer therapy. Adenoviral expression of Smac induced apoptosis in cells that exhibit disrupted activation of the mitochondrial apoptosis signaling pathway. There, Smac induced cell death irrespective of the loss of Bax or overexpression of Bcl-x L . In contrast, loss of caspase-3 expression in MCF-7 cells carrying a caspase-3 null mutation completely abrogated sensitivity for Smac-induced cell death, while re-expression of caspase-3 conferred sensitivity. These data and inhibitor experiments indicate that caspase-3 but not caspase-9 activation is a prerequisite for execution of Smac-induced cell death.
Results

Generation of Ad-Smac adenoviral vector for conditional expression of Smac
Previous studies indicated that Smac acts through disruption of the interaction between IAP proteins and caspases, thereby relieving inhibition of caspases by IAPs. In the case of caspase-3, such disruption of IAP binding was shown to result in the direct activation of caspase-3 in vitro . To further investigate the mechanisms of apoptosis induction via Smac and to test whether it is possible to overcome various types of apoptosis resistance in carcinoma cells by targeting this particular upstream regulator of the caspase cascade, we designed a replication-deficient adenoviral vector based on adenovirus serotype 5 to allow for conditional overexpression of Smac. Regarding the sensitizing effect of Smac on caspase activation , we aimed to express the proform of Smac. This proform of Smac contains the N-terminal mitochondrial targeting sequence required for import into the mitochondria. Once imported, the targeting sequence is cleaved off to yield the mature form of Smac that is released upon activation of the mitochondria during apoptosis .
To achieve the conditional expression of the Smac transgene, we constructed a single adenoviral vector based on the tetracycline-controlled transactivator (tTA) Tet-off system (Gossen and Bujard, 1992) . To this end, the cDNA coding for the full-length proform of human Smac was brought under control of an artificial mini-CMV promoter, containing seven repetitive binding domains (Tet-O(7)) for binding of the tTA, a chimeric fusion protein between the E. coli tet repressor and the activating domain of virion protein 16 (VP16) of Herpes simplex virus. This adenoviral system allows for the conditional expression of Smac upon activation of the tTA transactivator in the absence of tetracyclin or doxycyclin. To allow the detection of exogenous Smac, the protein was tagged at the Cterminus by the use of a Flag sequence. This construct was inserted into the E1-region of an E1a/E1b-deleted serotype 5 adenoviral vector. In addition, the tetracyclin/doxycyclin-inhibited tTA transactivator from the Tet-off system was inserted in cis under the control of a CMV promoter into the adenoviral E3 region to obtain the Ad5-Smac/Flag-tTA (Ad-Smac) vector (Figure 1a ). Correct sequence of the Smac and tTA expression cassettes was confirmed by DNA sequencing (data not shown). Recombination with E1 supplied in trans by the HEK293 producer cells resulting in replicationcompetent wild-type adenovirus was ruled out by polymerase chain reaction (PCR) for E1a as well as a plaque assay in A549 lung cancer cells (Anderson et al., 2000) . Transduction efficiency of Ad-Smac at an MOI of 10 was above 90% in all cell lines tested (including colon carcinoma HCT116, prostate carcinoma DU145, and breast carcinoma MCF-7 cells) as confirmed by infection with an Ad-lacZ control virus (data not shown).
Analysis of protein expression upon transduction of DU145 prostate carcinoma cells showed that both the immature proform and the processed Smac lacking the mitochondrial localization signal are expressed upon adenoviral gene transfer of Smac. This indicates the correct processing of the proform to the mature Smac protein. As protein expression was detected by the use of an anti-Flag tag antibody recognizing the C-terminal Flag epitope, both bands are derived from adenovirally expressed Smac (Figure 1b) . The conditional expression of Smac was induced in the absence of doxycyclin (Tet-on condition) and was completely suppressed in the presence of doxycyclin (Tet-off condition).
Ad-Smac induces apoptosis that is independent from Bax or Bcl-x L To our surprise, the adenoviral expression of Smac in human carcinoma cells directly triggered apoptosis. This suggests either that adenovirally expressed Smac is not confined to the mitochondria or that caspase activation may take place in the mitochondria themselves. To study whether apoptosis induction by Ad-Smac relies on activation of the mitochondria, for example, due to dependency on a mitochondrial activation loop as previously described for drug-induced apoptosis (von Haefen et al., 2003) , we investigated apoptosis induction by Smac in cells lacking the expression of the proapoptotic Bax protein. HCT116 cells carry one wildtype and one frameshift-mutated Bax allele and show an intact expression of wild-type Bax protein (Zhang et al., 2000) . In an isogeneic subline, the second allele was disrupted by targeted knockout resulting in HCT116 Bax À/À cells (Zhang et al., 2000) . In contrast, DU145 cells carry one silent Bax allele and a monoallelic frameshift mutation in the second Bax allele that introduces a premature stop codon and completely abrogates Bax protein expression (Gillissen et al., 2003) . Figure 2a shows that adenoviral expression of Smac induced a substantial amount of apoptosis in the absence of additional stimuli, as determined by flow cytometric measurement of cells undergoing DNA fragmentation. Thus, instead of only sensitizing for apoptosis, enforced expression of Smac appears to directly trigger execution of apoptotic cell death in human carcinoma cells. At an MOI of 10, infection with Ad-Smac induced apoptosis in 25% of the HCT116 Bax k.o. cells and in 40% of the Bax expressing HCT116 vector control cells in the absence of doxycyclin (Tet-on condition). In the Tet-off condition, that is, in the presence of doxycyclin, transduction with Ad-Smac was associated with accumulation of cells in G2/M that was apparent both in HCT116 cells (Figure 2a ) and DU145 cells (see below). This effect may therefore be attributed either to the use of the adenoviral vector system or a low level expression, that is, leakiness of Smac expression in the Tet-off condition. Nevertheless, less than 5% of the (Figure 2b ). This seemed to indicate that Smac induces apoptosis at least to some extent through a Bax-dependent mechanism. Nevertheless, both the HCT116 Bax k.o. cells and the HCT116 vector control cells exhibited apoptotic DNA fragmentation in 50% of the cells when tested at an MOI of 50 (Figure 2a, b) . This suggests that Smac-induced apoptosis is largely Bax-independent and does not require activation of a Bax-mediated mitochondrial activation loop. On the other hand, this also indicates that Smac can circumvent the apoptosis-resistant phenotype of Bax-deficient cells.
To corroborate this finding, we performed a similar experiment in Bax-deficient and in Bax-expressing DU145 cells where we re-introduced Bax by the use of a HyTK-Bax retroviral vector driving Bax expression under the control of a CMV promoter (Gillissen et al., 2003) . As in the HCT116 system, adenoviral expression of Smac strongly induced apoptosis in both the Baxdeficient and -proficient cells, thereby confirming that Smac triggers Bax-independent apoptosis in at least two human carcinoma cell lines employed in the present study ( Figure 3) .
Previously, we observed that adenoviral gene transfer of the apoptosis promoting p14 ARF induces apoptosis in a Bax-independent manner in both DU145 and HCT116 cells. Nevertheless, p14
ARF initiated apoptosis through a Bcl-2/Bcl-x L -dependent pathway (Hemmati et al., 2002) . To investigate if similar signaling events are triggered by Smac and to clarify whether Smac circumvents Bax deficiency but still activates the mitochondrial apoptosis signaling cascade through a Bcl-2 family-dependent mechanism, we analysed Ad-Smac-induced apoptosis in HCT116 cells stably overexpressing Bcl-x L as compared with mock transfectants (Figure 4a ). Overexpression of Bcl-x L conferred partial resistance to epirubicin induced apoptosis (Figure 4b ). In contrast, apoptosis was induced by Smac regardless of Bcl-x L overexpression (Figure 5a, b) . In addition, these data clearly demonstrate that Smac acts independently from Bax and Bcl-x L and may circumvent apoptosis deficiencies in cancer cells caused by loss of Bax or overexpression of antiapoptotic Bcl-2 homologs such as Bcl-x L .
Caspase activation by Ad-Smac and critical involvement of caspase-3
As Smac is supposed to exert its pro-apoptotic activities by enhancing caspase activation, we determined processing of the initiator caspase-9 and the executioner caspase-3 that are both subject to inhibition by IAP proteins. Figure 6 shows that adenoviral expression of Smac in HCT116 cells induces processing of caspase-9 and -3, as evidenced by Western blot analysis and detection of caspase subunits.
As a positive control, we employed the anthracyclin anticancer drug epirubicin, an inhibitor of topoisomerase IIa. There was, however, no significant processing of procaspase-9 after 24 h incubation with epirubicin, while caspase-3 cleavage to the active subunits was already detectable. This indicates that processing of caspase-3 during drug-induced apoptosis may occur in a caspase-9-independent manner. In fact, data obtained in caspase-3-deficient or -proficient MCF-7 cells (see below) indicate that Smac initially triggers caspase-3 processing that is a prerequisite for caspase-9 cleavage. Thus, caspase-3 processing in the absence of significant caspase-9 cleavage (as observed upon treatment with epirubicin) may very well be a consequence of release of endogenous Smac from the mitochondria. This cleavage of procaspase-3 to the active p16/p17 fragment upon epirubicin treatment was at least partially Bax dependent, while processing of caspase-3 to the p18 and p20 subunits occurred in a Bax-independent manner. Similar findings of partial independence from Bax were reported earlier in epirubicin-induced apoptosis (Hemmati et al., 2002) . Upon Ad-Smac infection for 24 h, caspase-3 and -9 processing occurred to an identical extent in the Baxproficient and the Bax knockout HCT116 cells. This indicates that Smac-induced caspase activation occurs in a fully Bax-independent manner. Both HCT116 lines express similar amounts of XIAP protein ( Figure 6 ).
To determine whether the induction of caspase activation leads to activation of apoptosis regulators implicated in mitochondrial feedback amplification, we determined caspase-8 and Bid cleavage in Ad-Smac transduced HCT116 cells ( Figure 6 ). Caspase-8 levels in HCT116 and other carcinoma lines studied here are, however, rather low when compared with caspase-8 levels detected in lymphoid malignancies. Nevertheless, Western blot analysis demonstrated that Smac triggers caspase-8 processing to the active p18 subunit. No caspase-8 cleavage was observed in HCT116 cells exposed to epirubicin for 24 h. At this early time point, caspase-3 and -8 processing were not paralleled by detectable Bid cleavage. There was no significant decrease in Bid protein levels and no tBid cleavage product was detectable either in cells induced for apoptosis by epirubicin or Ad-Smac ( Figure 6 ). Smacinduced apoptosis was already readily detectable at this time point. In view of the stringent dependence on caspase-3, this caspase-8 processing presumably occurs through a caspase-3-dependent, death receptor-independent mechanism as described earlier for drug-induced apoptosis. The functional relevance of this caspase-8 processing remains nevertheless to be established, especially in view of the need of induced proximity of caspase-8 in a complex with FADD or FLIP L to result in enzymatically active caspase-8.
To further address the role of mitochondria in AdSmac-induced apoptosis, we determined the release of cytochrome c upon exposure to Ad-Smac. Western blot analysis of cytosolic extracts obtained at 24-72 h post infection with Ad-Smac show that adenoviral Smac expression induces the release of cytochrome c in both Bax-deficient and Bax-expressing DU145 cells (Figure 7) . The release of cytochrome c into the cytosol is low at 24 and 48 h and reaches a maximum at 72 h after infection. Interestingly, the release of cytochrome c was slightly more pronounced in the Bax-proficient DU145 cells, indicating that a minor percentage of cytochrome c release occurs through a Bax-dependent mechanism in these cells. This may indicate that Smac initiates a Baxdependent amplification loop as observed earlier in the case of anticancer drug-induced cell death (Slee et al., 2000; von Haefen et al., 2003) . This putative amplification loop does, however, not appear to be relevant for execution of Smac-induced apoptosis. Cell death induction by Smac is, however, already significant at 24 h post infection with Ad-Smac in the absence of doxycyclin (Tet-on condition). No cytochrome c release was observed in the cells cultured in the presence of doxycyclin (Tet-off condition) up to 48 h after transduction. Thus, release of cytochrome c upon adenoviral expression occurs late and therefore secondary to caspase activation, that is, upon the final demise of the cell and its organelles.
To determine whether Smac-induced cytochrome c release and mitochondrial membrane potential breakdown requires caspase activation, we added the pancaspase inhibitor zVAD-fmk to cultures of DU145 cells transduced with Ad-Smac (Figure 8 ). The mitochondrial membrane potential (DC m ) was determined by flow cytometric measurement of red fluorescence after loading of the cells with the cationic dye JC-1. Cells with an intact DC m show a homogenously strong red staining of mitochondria, while cells with apoptotic mitochondria are characterized by loss of red fluorescence. Figure 8a shows that breakdown of the mitochondrial membrane potential as determined by staining with the cationic dye JC-1 is only marginally inhibited upon addition of zVAD-fmk at 20 mM. In contrast, the same dose of zVAD-fmk efficiently interferes with ceramide-induced apoptosis (Figure 8b ) or ceramide-induced loss of DC m as described earlier . This finding is supported by analyses of Smac-induced cytochrome c release (Figure 8c ). Addition of zVADfmk did not inhibit Ad-Smac-induced release of cytochrome c into the cytosol in Bax-negative DU145 cells. Nevertheless, a slight inhibition of cytochrome c release was observed in the Bax-expressing DU145 cells down to the level observed in the Bax-deficient DU145 cells. This is well in line with the data shown in Figure 7 . Therefore, part of the Smac-induced cytochrome c release occurs through a Bax-and caspase-dependent amplification loop. However, this Bax effect does not apparently contribute significantly to the induction of cell death by Smac. Moreover, these data indicate that the loss of DC m induced by Smac (Figure 8a ) and the Bax-independent release of cytochrome c do not depend on caspase activation. This delineates that Smac, like Omi/HtrA2, might also exert caspase-independent apoptotic functions.
To further investigate the mechanism of Smacinduced apoptosis, pan-caspase activities induced by Ad-Smac were measured on the single-cell level by flow cytometric determination of cells stained by the use of the peptide substrate VAD-FITC that binds to activated caspases. Conditional expression of Smac induced caspase activation 48 h after viral transduction in 50-70% of the DU145 or HCT116 cells, irrespective of the Bax or Bcl-x L expression status (Figure 9 ). Altogether, these data depict that Smac is an effector of the downstream apoptosis signaling that does not critically rely on the recruitment of upstream components of the signaling cascade such as Bax or Bcl-x L . To this end, we aimed to investigate and dissect the contribution of caspase subsets in the induction and execution of apoptosis by adenovirally expressed Smac. This was achieved by means of measuring the percentages of cells undergoing apoptotic DNA fragmentation upon conditional expression of Smac in the presence or absence of the pan-caspase inhibitor zVAD-fmk. Alternatively, zDEVD-fmk or zLEHD-fmk as inhibitors of caspase-3-like or caspase-9-like caspases were employed. These cell-permeable caspase inhibitors were added to the cultures at a concentration of 20 mM. Cells were incubated for 48 h in the presence of the inhibitors after infection of the cells with Ad-Smac until cell death was assessed by determination of genomic DNA fragmentation on the single-cell level. Previous data showed that the inhibitors are sufficiently dosed at 20 mM to efficiently inhibit the respective caspases while retaining their substrate specificity. Smac-induced cell death in the absence of doxycyclin (Tet-on condition) was almost completely inhibited when zVAD-fmk was added to both HCT116 (Figure 10a ) and DU145 cells (Figure  10b ), irrespective of their Bax expression status. Like zVAD-fmk, zDEVD-fmk or zLEHD-fmk strongly inhibited Smac-induced apoptosis. In HCT116, an almost complete inhibition of Smac-induced apoptosis, down to the levels observed upon the use of zVAD-fmk, was achieved by the use of zLEHD-fmk, whereas zDEVD-fmk inhibited Smac-induced apoptosis only by approximately 40%. In contrast, zDEVD-fmk showed a better inhibition as compared with zLEHDfmk in the DU145 cells. Thus, the dominant target for Smac appears to be caspase-9-like LEHDases in HCT116 cells as opposed to caspase-3-like DEVDases in the DU145 cells.
To further test the role of caspase-3 in apoptosis induced by adenoviral Smac expression on a genetic level, we employed caspase-3-mutated and therefore negative MCF-7 cells and compared these with MCF-7, where caspase-3 was stably re-expressed (Ja¨nicke et al., 1998; Friedrich et al., 2001) . Conditional expression of Smac induced apoptosis in the caspase-3-transfected MCF-7 but not in the caspase-3-negative control transfectants. Apoptotic DNA fragmentation was determined by flow cytometric measurement of the cellular DNA content. Hypodiploid cells started to be detectable 48 h after transduction of the cells with Ad-Smac and apoptosis was readily detectable in 50% of the caspase-3-expressing MCF-7 at 72 h ( Figure 11 ). In contrast, Smac-induced apoptosis was absent in MCF-7 mock transfectants lacking caspase-3. To corroborate these data, we determined caspase-9 and -3 processing and determined viability by the use of annexin-V-FITC/ propidium iodide staining (Figure 12 ). Western blot versus Bax reconstituted (black bars)) cells were cultured in medium alone (control) or were infected with Ad-Smac at 25 MOI in the presence or absence of 1 mg/ml doxycyclin. Broad-range pan-caspase inhibitor z-VAD-fmk, caspase-3-like (z-DEVD-fmk) and caspase-9-like inhibitor (z-LEHD-fmk) were added at a final concentration of 20 mM. After 48 h, cells were harvested and apoptosis was determined by analysis of genomic DNA contents by flow cytometry. Means7standard deviation of hypodiploid (apoptotic) cells from triplicates are shown Figure 11 Apoptosis induction by Ad-Smac is entirely caspase-3 dependent in MCF-7 cells. MCF-7 mock-transfected or caspase-3-expressing MCF-7 cells and C3-overexpressing cells were cultured for 48 h (a) or 72 h (b) in medium alone (control) or were infected with Ad-Smac at 25 MOI in the presence or absence of 1 mg/ml doxycyclin. Apoptosis was determined by analysis of genomic DNA contents by flow cytometry. Means7standard deviation of hypodiploid (apoptotic) cells from triplicates are shown analyses in cells harvested 36 h after transduction with Ad-Smac show that caspase-3-proficient MCF-7 cells have processed both caspase-3 and -9. This is paralleled by processing of the caspase-3 substrate PARP to the 85 and 25 kDa cleavage products. In contrast, the caspase-3-negative MCF-7 mock transfectants show only very weak PARP processing upon transduction with AdSmac (Figure 12a) . Likewise, no caspase-9 processing is detectable in the caspase-3-negative MCF-7 cells. Interestingly, caspase-3 and PARP processing is even more pronounced in MCF-7 cells treated with the anticancer drug epirubicin. This lack of PARP processing in the caspase-3-deficient MCF-7 mock cells is paralleled by a lack of cell death induction, that is, apoptosis (Figure  11b ) or necrosis (Figure 12b) , as determined by uptake of propidium iodide, that is, permeabilization of the cell membrane. In contrast, MCF-7 cells that are caspase-3 proficient undergo both apoptosis (Figure 11b ) and necrotic cell death (Figure 12b ) upon conditional expression of Smac.
These experiments demonstrate that Smac fully depends on caspase-3 to trigger execution of cell death whereas caspase-3-negative cells are protected from Smac-induced cell death. Moreover, these experiments delineate that caspase-3 is the main target of Smac, whereas execution of cell death and caspase-9 processing requires caspase-3.
Discussion
The release of pro-apoptotic factors from mitochondria is the decisive step for execution of the mitochondrial apoptosis cascade. These events include the release of cytochrome c and ATP into the cytosol to activate the APAF-1 adaptor protein. This initiates the assembly of the apoptosome that recruits and activates pro-caspase-9. Recently, additional pro-apoptotic factors were identified to be released from mitochondria (van Loo et al., 2002) . These include the apoptosis-inducing factor (AIF; Lorenzo et al., 1999) , endonuclease G (Li et al., 2001) , the serine protease Omi/HtrA2 (Suzuki et al., 2001) and Smac, the second mitochondrial activator of caspases . Smac was demonstrated to disrupt caspase inhibition by IAP proteins and to directly activate caspase-3 activation in vitro in a cellfree system . Apart from this direct effect on caspase activation, Smac was shown to amplify caspase activation following mitochondrial cytochrome c-induced activation of caspase-9 . Inhibition of IAP function is mediated by an N-terminal peptide motif that binds to the BIR3 domain of IAP proteins. This results in disruption of IAP binding to caspases. Recently, both Smac-b, a splice variant that lacks the N-terminal IAP-binding motif, and N-terminal truncation Smac mutants were shown to potentiate apoptosis (Roberts et al., 2001) . Thus, Smac appears to promote apoptosis through both IAP-dependent and independent mechanisms. Given its caspase-activating properties, Smac seems to be capable of both circumventing the requirement of cytochrome c release by direct activation of executioner caspases and to act as a sensitizer for caspase activation and apoptosis initiated through the mitochondrial pathway. Similar data were obtained for the murine Smac homolog Diablo (Ekert et al., 2001) . In addition, Smac peptides derived from the N-terminal motif required for disruption of caspase binding to IAPs were recently shown to sensitize tumor Figure 12 Induction of apoptotic and nonapoptotic cell death by Ad-Smac is entirely caspase-3-dependent in MCF-7 cells. (a) Western blot analysis. MCF-7 mock-transfected or C3-overexpressing cells were either infected with Ad-Smac at 25 MOI in the presence (Tet-off condition) or absence of 1 mg/ml doxycyclin (Teton condition), or were mock treated with medium alone (control) or treated with 1 mg/ml epirubicin as a positive control. Ad-Smactransduced cells were harvested 36 h after infection, epirubicintreated cells 24 h after drug exposure. Total cellular proteins (25 mg) were subjected to SDS-PAGE and subsequent Western blot analysis for the indicated proteins. In case of PARP detection, a 10% gel was applied. Equal loading was confirmed by reprobing with an antibody against b-actin. (b) MCF-7 mock-transfected or C3-overexpressing cells were infected with Ad-Smac at 25 MOI in the presence (Tet-off condition) or absence of 1 mg/ml doxycyclin (Tet-on condition), or were mock treated with medium alone (control). Cells were harvested 36 h after infection, stained with propidium iodide (PI) and subjected to flow cytometric analysis. Cells positive for PI, that is, showing membrane damage, were determined as necrotic or late apoptotic. Data are given as means7standard deviation from triplicates. White bars: medium control; shaded bars: Ad-Smac þ doxycyclin (Tet off condition); black bars: Ad-SmacÀdoxycyclin (Tet on condition) cells for either drug-or TRAIL-induced apoptosis (Fulda et al., 2002; Guo et al., 2002) .
In malignant tumors, the mitochondrial pathway of apoptosis is often disrupted. Such genetic events resulting in resistance to apoptosis play an important role not only in tumorigenesis but also during the secondary genetic events, leading to resistance to anticancer therapy. Previous studies established that such an inactivation of the mitochondrial pathway of apoptosis or defects in caspase activation correlate with poor prognosis and development of clinical resistance to anticancer therapy (Prokop et al., 2000; Sturm et al., 2001 Sturm et al., , 2003 Schelwies et al., 2002; Gu¨ner et al., 2003; Mrozek et al., 2003; Rau et al., 2003) .
We therefore addressed the functional role of Smac in cells with disrupted apoptosis signaling in consequence of loss of Bax, overexpression of Bcl-x L or inactivation of caspase-3. To this end, we constructed an adenoviral vector based on the Tet-off system (Gillissen et al., 2003) to allow for the conditional expression of Smac in human carcinoma cells.
Here, we show that the conditional expression of Smac induces apoptosis regardless of the propensity of the affected cells to activate the mitochondrial pathway of apoptosis. Thus, tumor cells lacking Bax or overexpressing Bcl-x L showed no defective apoptosis response when Smac protein expression was enforced. Data obtained in Bax-deficient and Bax-proficient cells indicate, however, that Smac triggers an amplification loop to release cytochrome c. Bax-dependent triggering of cytochrome c release is mediated by caspase activation and could be inhibited by the addition of zVADfmk. It remains to be established whether this occurs through a caspase-8-and Bid-dependent pathway. This loop, nevertheless, only partially depends on the presence of Bax and is functionally irrelevant for the execution of Smac-induced apoptosis. This is remarkable since caspase-3 and -8 and the BH3-only protein Bid were previously shown to promote a positive feedback loop during mitochondrial apoptosis induction by anticancer drugs (von Haefen et al., 2003) . In contrast to such conventional anticancer drugs, Smac induced release of cytochrome c late during apoptosis, that is, starting at 48 h after Smac expression. This indicates that Smac is a crucial factor that mediates late events in apoptosis such as disintegration of mitochondria. Nevertheless, the targeted knockout of the murine Smac gene does not result in a distinct phenotype (Okada et al., 2002) . This would rather suggest that Smac helps but is not decisive to execute apoptosis.
A significant portion of cytochrome c release induced by Smac into the cytosol occurs through a Bax and caspase independent pathway. Likewise, breakdown of the mitochondrial membrane potential occurs in a Bax and Bcl-x L independent manner that cannot be prevented by the pan-caspase inhibitor zVAD-fmk. This delineates a caspase independent mode of action of Smac, in analogy to the serine protease Omi/HtrA2. In this vein, we cannot exclude that Smac or Ad-Smac might signal via Bak to trigger mitochondria to release cytochrome c. Both HCT116 and DU145 express significant amounts of Bak (Gillissen et al., 2003) . Nevertheless, Smac-induced apoptosis in HCT116 cells was not sensitive to inhibition by Bcl-x L , whereas epirubicin-induced cell death was attenuated. Thus, a participation of Bak during Ad-Smac-induced apoptosis does not seem to be relevant as Bak activation and oligomerization would be sensitive to inhibition by Bcl-x L .
Smac-induced apoptosis was executed via a predominantly caspase-3-dependent pathway as expected and previously described Du et al., 2000) . Interestingly, the lack of caspase-3 in MCF-7 cells completely abrogated Smac-induced apoptosis or nonapoptotic necrosis like death. Thus, Smac is fully capable of triggering the execution of apoptosis in the absence of mitochondrial activation, but completely relies on the presence of caspase-3 that appears to be the major executioner of Smac-induced apoptosis. In caspase-3-deficient MCF-7 cells, no significant caspase-9 processing was observed, whereas caspase-9 was readily cleaved in caspase-3-expressing MCF-7 cells. Therefore, caspase-9 is processed downstream of caspase-3 during Smac-induced apoptosis. This also indicates, together with the inhibitor experiments described above, that caspase-9 (or other Smac-activated caspases) might be insufficient to fully activate the apoptosis execution machinery in this system of conditional Smac expression in the absence of caspase-3. Since the inhibitor experiments performed by the use of cell-permeable LEHD peptides showed that caspase-9 and other LEHDases play a prominent role in mediating execution of Smac-induced apoptosis, this would place caspase-9 downstream of caspase-3 in the present setting. Nevertheless, one should keep in mind that caspase-9 activation does not necessarily rely on caspase-9 cleavage. Generation of enzymatically active caspase-9 species may occur in the apoptosome complex upon induced proximity in the absence of caspase-9 cleavage. The data obtained in MCF-7 cells indicate, however, that such a caspase-9 activation in the absence of caspase-9 processing would not be sufficient for execution of apoptosis upon Smac expression in the absence of caspase-3.
Altogether, our findings provide novel insights into how Smac mediates apoptosis. Finally, we demonstrated that adenoviral overexpression of Smac not only circumvents apoptosis deficiency caused by overexpression of Bcl-x L but also defects that occur in consequence of loss of Bax. Thus, Smac itself and Smac mimics such as the recently described Smac-derived peptides could represent promising tools to overcome such resistant genotypes.
Materials and methods
Cell culture
Control vector (pcDNA3-transfected) and pcDNA3-caspase-3-transfected MCF-7 cells (Ja¨nicke et al., 1998; Friedrich et al., 2001) were grown in Roswell Park Memorial Institute (RPMI) 1640 medium, HEK293 and DU145 were grown in DMEM/ high glucose (4.5 g/l) medium and HCT116 cells were grown in McCOY'S 5A medium. All media were supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 0.1 mg/ml streptomycin (all from GIBCO/Invitrogen, Karlsruhe, Germany) and cells were cultured at 371C with 5% CO 2 in fully humidified atmosphere. HEK293 and DU145 were obtained from the ATCC (Manassas, VA, USA), or the DSMZ (Braunschweig, Germany). HCT116-Bax knockout cells as well as the corresponding isogeneic Bax-proficient control HCT116 cells were kindly provided by Dr. Bert Vogelstein. DU145-Bax, HCT116-Bcl-x L and the corresponding mock transfectants were generated as described below.
Stable expression of Bax by retroviral infection of DU145 cells
Stable expression of Bax in the Bax-mutated DU145 cells was achieved by means of the retroviral vector HyTK-Bax, which contains the human Bax-a cDNA under the control of a CMV promoter, together with a hygromycin resistance-HSV thymidine kinase fusion gene under the control of the retroviral LTR (Hemmati et al., 2002) . Supernatant of the virus-producing packing cell line FLYRD-18 (Cosset et al., 1995) was used to infect DU145 cells in the presence of 8 mg/ml polybrene (Sigma-Aldrich, Gru¨nwald, Germany). Hygromycin (0.5 mg/ ml, GIBCO) was added 48 h later. Cells were selected under antibiotic pressure and stable transfectants were subcloned. Vector integration of the transgene was confirmed by vectorspecific genomic PCR and Bax expression was determined by Western blot analysis.
Stable expression of Bcl-x L by retroviral infection of HCT116 cells
HCT116 cells stably expressing Bcl-x L were generated by use of the retroviral vector pBabe-Puro-Bcl-x L . Supernatant of the virus-producing packing cell line FLY-A13 (Cosset et al., 1995) was employed to infect HCT116 cells in the presence of 8 mg/ml polybrene (Sigma-Aldrich). Puromycin (1 mg/ml, GIB-CO) was added 48 h later and following 3 weeks of selection stable transfectants were subcloned. Bcl-x L expression of several individual clones was determined by Western blot analysis.
Construction of recombinant conditional Tet-off Smac adenovirus
The method for production of recombinant, replicationdeficient adenoviral vectors is a modification of the procedure described earlier (Gillissen et al., 2003) . Adenoviral plasmids were kindly provided by HepaVec AG (Berlin, Germany). To insert the tTA expression unit into the adenovirus genome, the tTA expression cassette from pTet-Off (Gossen and Bujard, 1992; Clontech, Heidelberg, Germany) was first cloned as a XhoI/PvuII fragment into pHVAd3, an adenoviral shuttle vector for the E3 region. The virus genome containing the tTA expression unit was generated in the E. coli strain BJ5183 RecBC-sbcB by homologous recombination of the shuttle plasmid with pHVAd1 (containing the complete adenovirus genome) resulting in plasmid pAd-tTA. For the construction of an inducible Smac/Flag expression cassette, the XhoI/EcoRI fragment from pTRE (Clontech) containing the tetracyclineresponsive-element (TRE) upstream of the CMV minimal promoter was inserted into the adenoviral shuttle vector pHVAd2. C-terminally Flag-tagged human Smac cDNA was generated as described and was cloned via the HindIII/XbaI restriction sites into the pHVAd2 þ TRE shuttle plasmid, resulting in pAd-TRE-Smac. Restriction sites have been inserted by PCR using the following primers: 'Smac-Hind forward': 5 0 -CCC AAG CTT ATG GCG GCT CTG AAG AG-3 0 and 'Smac-Xba reverse': 5 0 -GCT CTA GAT TAC TTG  TCG TCG TCG TCC-3 0 . The sequence integrity of the amplification product was confirmed by DNA sequencing. The resulting TRE-Smac/Flag shuttle expression unit was inserted into the Ad5 virus genome by homologous recombination of the shuttle plasmid with pAd-tTA, thereby replacing the E1 region and creating pAd5-Smac-tTA. The viral DNA was transfected into HEK293 cells and adenoviral plaques were propagated according to standard procedures including some modifications as described before (Brand et al., 1997) . Cells were infected with the resulting Ad-tTA-Smac recombinant, replication-deficient adenovirus diluted in cell culture medium in the absence of FCS or antibiotics at the indicated multiplicity of infection (MOI) for 1.5 h at 371C, or were mock treated with serum-free medium only. Thereafter, equal amounts of medium supplemented with 20% FCS, 200 U/ml penicillin and 0.2 mg/ml streptomycin were added. Expression of Smac was efficiently suppressed by addition of doxycyclin to the respective culture medium at a concentration of 1 mg/ml.
Antibodies and reagents
Mouse monoclonal anti-Flag M2, HRP conjugate antibody was purchased from Upstate Biotechnology (Lake Placid, NY, USA) and used at a dilution of 1 : 1000 in Western blot analysis. Mouse monoclonal anti-Bax antibody (clone YTH-2D2, raised against a synthetic peptide corresponding to amino acids (aa) 3-16) was purchased from Trevigen (Gaithersburg, MD, USA) and used at a dilution of 1 : 10 000. Mouse monoclonal anti-cytochrome c antibody (clone 7H8.2C12) was from BD-Pharmingen (Heidelberg, Germany), rabbit antiactin antibody was from Sigma-Aldrich. Both were used at a dilution of 1 : 500. Goat polyclonal antibodies against caspase-3 and -9 and a rabbit polyclonal against Bid were from R&D Systems (Wiesbaden, Germany) and were used at a dilution of 1 : 2000. Monoclonal mouse anti-caspase-8 antibody (clone 1C12) and rabbit polyclonal anti-PARP were purchased from Cell Signaling Technology (Beverly, MA, USA), and were used at a dilution of 1 : 1000. Rabbit polyclonal anti-Bcl-x L antibody and mouse anti-XIAP antibody were both from BD Transduction Laboratories (Los Angeles, CA, USA) and used at a dilution of 1 : 1000 and 1 : 500, respectively.
All antibodies were diluted in PBS supplemented with 0.05% Tween-20 (PBS-T) containing 3% non-fat dry milk. Secondary goat-anti-mouse and goat-anti-rabbit IgG antiserum coupled to horseradish peroxidase (HRP) were from Promega Corporation (Madison, WI, USA) and were used at dilutions of 1 : 2500 and 1 : 10 000, respectively, in PBS-T containing 3% nonfat dry milk. Secondary donkey-anti-goat IgG antiserum coupled to HRP was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and was used at a dilution of 1 : 2500 in PBS-T containing 3% nonfat dry milk. JC-1 (5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolyl-carbocyanine iodide) was from Molecular Probes (Leiden, The Netherlands). Pan-caspase Inhibitor z-VAD-fmk, caspase-3 inhibitor z-DEVD-fmk and caspase-9 inhibitor z-LEHD-fmk were from Calbiochem (Bad Soden, Germany). RNase A was from Roth (Karlsruhe, Germany). Epirubicin was purchased from Pharmacia Upjohn (Erlangen, Germany).
Immunoblotting
After trypsinization, cells were collected by centrifugation at 300 g at 41C for 5 min, washed twice with ice-cold PBS and lysed in appropriate amounts of lysis buffer (10 mM Tris/HCl, pH 7.5, 300 mM NaCl, 1% Triton X-100, 2 mM MgCl 2 , 5 mM EDTA) supplemented with protease inhibitors (1 mM pepstatin, 1 mM leupeptin and 0.1 mM phenylmethylsulfonyl fluoride) for 30 min on ice. Samples were centrifuged at 10 000 g, 41C for 15 min and the concentration of total cellular protein was determined from the supernatants using the bicinchoninic acid assay from Pierce (Rockford, IL, USA) as described. Thereafter, samples were mixed with sample buffer (125 mM TrisHCl, 288 mM b-mercaptoethanol, 20% glycerol, 2% SDS, 10 mg/ml bromophenol blue), boiled for 5 min, and equal amounts of protein (25 mg) were separated by SDS-PAGE using 16% gels. Immunoblotting was performed as described. Briefly, nitrocellulose membranes (Schleicher & Schuell; Dassel, Germany) were rinsed in transfer buffer (10 mM 3-(cyclohexylamino) propane-1-sulphonic acid, pH 11, 10% methanol) for 5 min, and blotting was performed at 1 mA/ cm 2 for 1 h in a transblot semi-dry blot cell (BioRad, Mu¨nchen, Germany). Thereafter, membranes were blocked for 1 h in blocking buffer (PBS-T, 3% non-fat dry milk) and incubated with primary antibodies at 41C overnight. After three washes with blocking buffer, membranes were incubated with secondary antibody for 1 h. Finally, the membranes were washed three times in PBS-T and protein bands were visualized using the enhanced chemiluminescence (ECL) system and exposed to Hyperfilm (both Amersham-Buchler, Braunschweig, Germany). For control of equal protein loading, membranes were stripped in 62.5 mM Tris-HCl (pH 6.8) supplemented with 100 mM b-mercaptoethanol and 2% SDS at 551C for 5 min, washed three times with PBS-T and reprobed with an antibody against b-actin.
Preparation of cytosolic protein fractions for measurement of cytochrome c release Cells were collected at the indicated time points by centrifugation at 300 g, 41C for 5 min and washed with PBS. The pellet was resuspended and incubated for 5 min on ice in hypotonic lysis buffer (20 mM HEPES (pH 7.4), 10 mM KCl, 2 mM MgCl 2 , 1 mM EDTA) supplemented with 0.1 mM PMSF and 0.75 mg/ml Digitonin (Sigma-Aldrich). Thereafter, debris was pelleted and the supernatants were subjected to Western blot analysis.
Measurement of apoptotic cell death by flow cytometry
Apoptosis was determined on the single-cell level by measuring the DNA content of individual cells by flow cytometry as described (Daniel et al., 1999) . Briefly, cells were seeded at a density of 1 Â 10 5 cells in six-well plates, cultured overnight and infected with Ad-Smac under serum-free conditions. After 24-72 h, cells were trypsinized and collected by centrifugation at 300 g for 5 min, washed once with PBS at 41C and fixed in PBS/2% (v/v) formaldehyde for 30 min on ice. Thereafter, cells were incubated in 70% ethanol/PBS (v/v) for 20 min on ice, pelleted and resuspended in PBS containing 40 mg/ml DNasefree RNase A (Roche Molecular Biochemicals, Mannheim, Germany). After incubation for 30 min at 371C, cells were pelleted again and resuspended in PBS containing 50 mg/ml propidium iodide (PI; Sigma-Aldrich). Cellular DNA content was measured with a logarithmic amplification in the FL-3 channel of a FACScan flow cytometer (Becton Dickinson, Heidelberg, Germany) equipped with the CELLQuest software. Data are given in percent hypoploidy (i.e. the percentage of cells with a sub-G1 DNA content), which reflects the percentage of apoptotic cells with fragmented genomic DNA. To determine apoptotic and nonapoptotic, that is, necrotic cell death, cells were stained with annexin-V-FITC and counterstained with PI. Annexin-V-FITC binds to phosphatidylserine (PS) in the outer leaflet of the plasma membrane. PI is not taken up by cells with intact cell membranes. Uptake of PI is therefore a sign of necrosis, whereas cells positive for annexin-V but negative for PI are generally defined as apoptotic. Briefly, to quantitate apoptosis, cells were washed twice with cold PBS and resuspended in buffer (10 mM N-(2-hydroxyethyl)piperazin-N 0 -3(propansulfonicacid)/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) at 1 Â 10 5 cells/ml. Next, 2 ml of annexin-V-FITC (BD Pharmingen, Heidelberg, Germany) and 4 ml PI (20 mg/ml, Sigma-Aldrich) were added to 100 ml cell suspension. Analyses were performed using FACScan (Becton Dickinson, Heidelberg, Germany) and CellQuest analysis software.
Measurement of the mitochondrial permeability transition
Cells were harvested by trypsinization and washed once in PBS at 48 h post infection with recombinant adenoviruses or mock treatment. Mitochondrial permeability transition was determined by staining of the cells with 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethyl-benzimidazolylcarbocyanin iodide (JC-1; Molecular Probes, Leiden, The Netherlands) as described. Briefly, equal numbers of cells (1 Â 10 5 ) were incubated with JC-1 at 2.5 mg/ml in 1 ml PBS for 30 min at 371C with moderate shaking. Cells were then centrifuged at 300 g, 41C for 5 min, 
